Previous 10 | Next 10 |
Esperion Therapeutics ( NASDAQ: ESPR ) is scheduled to announce Q4 earnings results on Tuesday, February 21st, before market open. The consensus EPS Estimate is -$0.85 (vs. -$1.77 last year) and the consensus Revenue Estimate is $20.6M (+33.8% Y/Y). Over the last 1 year, ESPR ...
ANN ARBOR, Mich., Feb. 20, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) announces that the landmark C holesterol L owering via B e mpedoic acid, an A CL-Inhibiting R egimen (CLEAR) Outcomes trial will be presented as a late-breaking clinical trial at th...
Summary Esperion Therapeutics released positive top-line data from its CLEAR Outcomes trial illustrating Nexletol met its primary endpoint. The market's price response was weak, however, instead resulting in a large sigma move to the downside. Shares are yet to recover, and the tren...
ANN ARBOR, Mich., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report fourth quarter and full year 2022 financial results before the open of the U.S. financial markets on Tuesday, February 21, 2023. Following the release, company management will host a w...
CONCORD, N.C., Jan. 11, 2023 (GLOBE NEWSWIRE) -- RFK Racing has announced that Esperion Therapeutics, a Michigan-based pharmaceutical company, has partnered with the team for a multi-year agreement pursuant to which Esperion will promote two cholesterol lowering treatments – NEXLIZET...
Esperion ( NASDAQ: ESPR ) expects fourth quarter 2022 U.S. net product revenue to be between $14.4M-$15.1M; full year growth between 38% and 40% Y/Y. The company also said that based on the robustness of the CLEAR Outcomes data across primary and secondary endpoints, company ...
– Based on the robustness of the CLEAR Outcomes data across primary and secondary endpoints, Company anticipates global regulatory submissions in 1H 2023 and believes it is entitled to receive milestone payments from partners upon regulatory approvals – – Fourth qua...
– Positive CLEAR Outcomes data to be presented as a Late-Breaking Clinical Trial (LBCT) at ACC.23/WCC on March 4, 2023 – – Bempedoic acid becomes the first ATP citrate lyase inhibitor and first oral non-statin to meet the major adverse cardiovascular events ( ...
ANN ARBOR, Mich., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) announced today that the Company plans to present at the J.P. Morgan 41 st Annual Healthcare Conference as well as the LifeSci Partners 12 th Annual Corporate Access Event. Both in-person events are taking place J...
Esperion ( NASDAQ: ESPR ) said Nexletol met the main goal of reducing major adverse cardiovascular events (MACE-4) in a phase 3 trial. The Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting Regimen (CLEAR) Outcomes trial included 14,000 patients and evaluated 180...
News, Short Squeeze, Breakout and More Instantly...
Esperion Therapeutics Inc. Company Name:
ESPR Stock Symbol:
NASDAQ Market:
Esperion Therapeutics Inc. Website:
ANN ARBOR, Mich., July 25, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report second quarter 2024 financial results before the market opens on Monday, August 12, 2024. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financi...
ANN ARBOR, Mich., July 24, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the BTIG Biotech Conference on Monday, August 5, 2024, at 4 p.m. ET. Esperion Therapeutics At Esperion, we discover, develop, and commercialize innovat...
– Targeted Campaign Reaches Patients at Risk for Heart Attack or Heart Procedures Because of High LDL Cholesterol (LDL-C) – – Animated Characters Are a Visual Representation of An Unseen Risk “Lurking” In Patients’ Artery Walls &...